Precirix

📍 Brussels, Belgium🗓 Founded 2014👥 43 employees💰 Last funded Oct 2019
PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline. PRECIRIX' technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.
8
Total investors
1
Early stage
7
Mid stage
0
Late stage
2014
Founded
Investor geography4 countries
Belgium
5
Sweden
1
Netherlands
1
Switzerland
1
Investor activity2014–2019 · investors recorded per year
201412018520192
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Precirix?
Precirix has 8 investors on record on gritt.io, including 1 early-stage backers, 7 mid-stage.
When did Precirix last raise funding?
The most recent investment in Precirix recorded on gritt.io was in October 2019.
When was Precirix founded?
Precirix was founded in 2014.
What industry is Precirix in?
Precirix operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Precirix based?
Precirix is headquartered in Brussels, Belgium.